How do you approach ILD monitoring when selecting Dato-DXd in frontline TNBC treatment?

ILD rates were very low in TROPION-Breast02, with less than 1% Gr3 or higher. I would follow recommendations per the FDA label and have an awareness of rare potential risk and counsel patients to alert clinical teams should they have symptoms of ILD.

Datopotamab deruxtecan (Dato-DXd) carries a boxed-warning-level risk of ILD/pneumonitis, and the FDA label mandates monitoring for new or worsening respiratory symptoms (dyspnea, cough, fever) throughout treatment, with immediate withholding if ILD is suspected and permanent discontinuation for conf...

TROP2-directed antibody-drug conjugates (ADCs) demonstrate efficacy across various solid tumors. Interstitial lung disease (ILD) represents a significant adverse effect, particularly with ADCs containing the deruxtecan (DXd) payload [1]. Similar to trastuzumab deruxtecan, dato-deruxtecan (Dato-DXd) ...